Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.724429
Keywords
CD86; CD163; ratio; recurrence; colorectal cancer; macrophage
Categories
Funding
- High-level Talents Project of Liuzhou People Hospital [lrygcc202106]
- Basic Research Ability Improvement Project of Young and Middle-aged Teachers from Guangxi colleges [2021KY0111]
- Self-funded project of Health Committee of Guangxi Zhuang Autonomous Region [Z20190901]
Ask authors/readers for more resources
The ratio of stromal CD86+TAM/CD163+TAM (CD86/CD163) was investigated as a prognostic biomarker for colorectal cancer, with results showing its effectiveness in predicting recurrence-free survival and overall survival. The ratio was found to be an independent predictor in different cohorts and showed better predictive values than tumor stage. The stromal CD86/CD163 ratio could be useful for individual risk assessment and personalized treatment in stage II-III colorectal cancer.
Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC). Two independently clinical cohorts of stage II-III CRC were retrospectively enrolled in this study. TAMs were detected using immunohistochemical staining for CD86 and CD163. The stromal CD86/CD163 ratio was calculated as a prognostic biomarker for recurrence-free survival (RFS) and overall survival (OS). Patients with a low CD86/CD163 ratio had shorter RFS (HR=0.193, p<0.001) and OS (HR=0.180, p<0.001) than patients with a high CD86/CD163 ratio in the training cohort. CD86/CD163 ratio may be an independent predictor for RFS (HR=0.233, p<0.001) and OS (HR=0.224, p<0.001) in the training cohort. We obtained equivalent results in the validation cohort. The CD86/CD163 ratio tends to have better predictive values than tumor stage in the training (AUC: 0.682 vs 0.654, p=0.538) and validation (AUC: 0.697 vs 0.659, p=0.586) cohorts. CD86/CD163 ratio effectively predicts RFS for stage II (HR=0.203, p<0.001) and stage III CRC (HR=0.302, p<0.001). CD86/CD163 ratio also effectively predicts RFS in CRC patients with adjutant chemotherapy (HR=0.258, p<0.001) and without adjutant chemotherapy (HR=0.205, p<0.001). The stromal CD86/CD163 ratio could be used for individual risk assessment of recurrence and mortality for stage II-III CRC. Together with tumor stage, this ratio will aid in the personal treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available